AMGEN INC. $750,000,000 2.125% SENIOR NOTES DUE 2020 $500,000,000 2.700% SENIOR NOTES DUE 2022 $1,000,000,000 3.125% SENIOR NOTES DUE 2025 $1,250,000,000 4.400% SENIOR NOTES DUE 2045 Underwriting AgreementUnderwriting Agreement • May 1st, 2015 • Amgen Inc • Biological products, (no disgnostic substances) • New York
Amgen Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of $750,000,000 principal amount of its 2.125% Senior Notes due 2020 (the “2020 Notes”), $500,000,000 principal amount of its 2.700% Senior Notes due 2022 (the “2022 Notes”), $1,000,000,000 principal amount of its 3.125% Senior Notes due 2025 (the “2025 Notes”) and $1,250,000,000 principal amount of its 4.400% Senior Notes due 2045 (the “2045 Notes”, and together with the 2020 Notes, 2022 Notes and the 2025 Notes, the “Securities”) to be issued pursuant to the provisions of an Indenture dated as of May 22, 2014 (the “Indenture”), between the Company and The Bank of New York Mellon Trust Company, N.A., as Trustee (the “Trustee”). Morgan Stanley & Co. LLC, Credit Suisse Securities (USA) LLC, Goldman, Sachs & Co. and Merrill Lynch, Pierce, Fenner & Smith Incorporated have agreed t
